Gatekeeper Mutations and Intratumoral Heterogeneity in <i>FGFR2</i>-Translocated Cholangiocarcinoma.
MetadataShow full item record
<b/><i>FGFR2</i> genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations in <i>FGFR2</i> and intratumoral heterogeneity drive resistance in patients with <i>FGFR2</i>-translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic. <i>Cancer Discov; 7(3); 248-9. ©2017 AACR.</i><i>See related article by Goyal et al., p. 252</i>.
Version of record
Bile Ducts, Intrahepatic
Bile Duct Neoplasms
Receptor, Fibroblast Growth Factor, Type 2
License start date
Cancer discovery, 2017, 7 (3), pp. 248 - 249